PRCT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Procept BioRobotics Corp (PRCT) is not a strong buy for a beginner, long-term investor at this moment. While there is insider buying activity and some positive financial trends, the company's recent financial performance, analyst sentiment, and lack of significant positive catalysts suggest that it is better to hold off on investing until clearer growth signals emerge.
The MACD is positive but contracting, indicating a weakening bullish momentum. RSI is neutral at 43.269, and moving averages are converging, showing no clear trend. The stock is currently trading near its pivot level of 24.487, with resistance at 25.71 and support at 23.265.
Insiders are buying, with a 1235.17% increase in the last month. Revenue and net income showed YoY improvements in Q4 2025, with net income improving by 58.28% YoY.
Hedge funds are selling, with a 465.92% increase in selling activity. Analysts have downgraded the stock, citing disappointing Q4 results, reduced guidance, and strategic challenges. Gross margin dropped by 5.27% YoY. No recent news or significant positive events to drive sentiment.
In Q4 2025, revenue increased by 11.94% YoY to $76.38M, net income improved by 58.28% YoY to -$29.85M, and EPS increased by 51.43% YoY to -0.53. However, gross margin dropped to 60.63%, down by 5.27% YoY.
Analyst sentiment is mixed to negative. Recent downgrades and lowered price targets dominate, with concerns about strategic execution and financial performance. The average price target is $30, but analysts express uncertainty about the company's ability to meet growth expectations.
